



ASX/MEDIA RELEASE

25 July 2018

Relocation of CEO to Boston

Sydney, Australia

Sirtex Medical Limited (ASX:SRX) (**Sirtex**) today announces the relocation of Mr Andrew McLean, CEO of Sirtex from the Sydney corporate headquarters to our Americas office in Boston, Massachusetts.

Mr McLean commented "The decision for me to relocate to our Americas office just outside of Boston makes sound strategic sense for the business, given the Americas accounts for a significant percentage of our global dose sales, the majority of our clinician customers are based within the US, and we own and operate a manufacturing facility in close proximity to our US headquarters. I would like to take the opportunity to thank our wonderful Sydney based staff for their support over the last 12 months during my time in the office."

Given the relocation, Mr McLean has entered into a new employment agreement with Sirtex Medical, Inc. The material terms of Mr McLean's new employment agreement are shown in Appendix 1.

– ENDS –

About Sirtex Medical, www.sirtex.com

Sirtex Medical Limited (ASX:SRX) is an Australian based medical device company with global market coverage. Its core revenue producing technology, which has regulatory approvals, is a selective internal radiation therapy (SIRT), with clinically proven applications for liver cancer with over 86,000 doses supplied and administered at over 1,160 medical centres in more than 40 countries.

Investor Enquiries:

Mr Andrew McLean
CEO
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy
Global Head of Investor Relations &
Corporate Development
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

To subscribe to our email alert service for ASX Announcements, please visit:
<http://www.sirtex.com/au/investors/email-alerts/>

Follow us on Twitter: **@sirtexmedical**
Visit us on LinkedIn: **Sirtex Medical Limited**

Head Office
Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas
300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa
Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific
50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406

APPENDIX 1

Commencement Date with Sirtex Medical, Inc.	1 August 2018 (though prior service with Sirtex Medical Limited is recognised as service with Sirtex Medical, Inc.)
Term	No fixed term
Base Annual Gross Salary	US\$634,000 per annum
Short Term Incentive	<p>50% of Total Fixed Remuneration salary subject to individual and company performance and is provided in cash.</p> <p>STI participation and terms is at the absolute discretion of the board.</p>
Long Term Incentive	<p>100% of Total Fixed Remuneration</p> <p>The Sirtex Executive Rights Plan provides executive employees with an 'at risk' component of remuneration based on company performance over a three year period and is delivered as equity if specific hurdles are met.</p> <p>Participation in the LTI Plan is subject to the absolute discretion of the board.</p>
Relocation Allowance	Certain relocation expenses (Repayable by Mr McLean if his employment is voluntarily terminated within one year of commencement of his employment with Sirtex Medical, Inc.).
Termination of Employment from Sirtex Medical, Inc.	Twelve months' notice in writing from either party. Sirtex may terminate Mr McLean's employment with immediate effect for cause.